Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,588 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Descriptive Clear all
Completed Not applicable Interventional

NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia

NCT06653829
View directory record Official record
Conditions
Negative Symptoms in Schizophrenia, Schizophrenia, Schizoaffective Disorder
Interventions
SPARK
Device
Lead sponsor
North Shore Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

The Effectiveness of Kuvan in Amish PKU Patients

NCT02677870
View directory record Official record
Conditions
Phenylketonuria
Interventions
saproterin dihydrochloride, Diet treatment
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 25, 2026, 10:13 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

NCT04759586
View directory record Official record
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Completed No phase listed Observational Results available

Home or Away From Home - Descriptive Interviews (Aim 2)

NCT02794207
View directory record Official record
Conditions
Pediatric Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 22 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Palo Alto, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 25, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages

NCT00758992
View directory record Official record
Conditions
Immunodeficiency
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurobehavioral Effects of Prenatal Mindfulness Training on Maternal Presence and Compassionate Love

NCT05241600
View directory record Official record
Conditions
Maternal-Fetal Relations, Mother-Child Relations, Maternal Behavior
Interventions
Mindfulness-Based Childbirth and Parenting, Non-Mindfulness-Based Childbirth Class
Behavioral
Lead sponsor
Heidemarie Laurent
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Champaign, Illinois • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

NCT04144036
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg, Neihulizumab
Biological · Drug
Lead sponsor
Sameem M. Abedin, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 25, 2026, 10:13 PM EDT
Active, not recruiting Phase 2 Interventional

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

NCT03147612
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Texas 2017 (H3N2) Challenge Study

NCT06476275
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Influenza A/Texas/71/2017 (H3N2), Sham placebo
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 46 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 25, 2026, 10:13 PM EDT
Recruiting Not applicable Interventional

Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

NCT07337590
View directory record Official record
Conditions
Colorectal Cancer
Interventions
xBar™ System
Device
Lead sponsor
Exero Medical Ltd.
Industry
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Lincoln, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Interventions
Dasatinib, Methotrexate, Prednisone, Rituximab, Venetoclax, Blinatumomab, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Dietary Added-Sugar Consumption During the Transition to College

NCT05823597
View directory record Official record
Conditions
Dietary Added Sugar Consumption
Interventions
Sugar Intensive Treatment, General Health Control
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 25, 2026, 10:13 PM EDT
Not listed Not applicable Interventional

Pectin Use in Pediatric Intestinal Rehabilitation

NCT04224168
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Green Beans, Liquid Pectin
Dietary Supplement
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
6 Months to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

The Gamma Pod: A Clinical Feasibility Study Device GCC 1202: The Gamma Pod: A Clinical Feasibility Study

NCT02507960
View directory record Official record
Conditions
Breast Cancer
Interventions
The Gamma Pod, CT simulation
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 25, 2026, 10:13 PM EDT
Recruiting Phase 2Phase 3 Interventional

The Many Roads to Trauma Recovery: A Clinical Trial Comparing Empirically Supported Treatments for Veterans With Co-Morbid Posttraumatic Stress and Substance Use Disorder Symptoms

NCT07756723
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Substance Use Disorder (SUD)
Interventions
Trauma Informed Heart Rate Variability Biofeedback, Present Centered Therapy
Behavioral
Lead sponsor
Coatesville VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Coatesville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

KETODEX for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery

NCT03779282
View directory record Official record
Conditions
Emergence Delirium, Strabismus
Interventions
Dexmedetomidine
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Jefferson, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 25, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication

NCT04289623
View directory record Official record
Conditions
Health Promotion, Wellness Program
Interventions
Email, Loss frame, Testimonial (medical expert), Testimonial (rank-and-file), Social norms (percentage), Social norms (number)
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
13,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Depression Interventions After Acute Coronary Syndrome

NCT01032018
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression
Interventions
Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care
Behavioral · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Montclair, California • Rialto, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Episodic Future Thinking and Weight-Loss

NCT03731325
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Episodic Future Thinking Group
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
10 Years to 14 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 25, 2026, 10:13 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Modifying Diet to Improve Gut Microbiome

NCT03924778
View directory record Official record
Conditions
Obesity
Interventions
DASH diet, standard American diet
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

Visual-acoustic Intervention With Service Delivery In-person and Via Telepractice Trial

NCT06517225
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Visual-acoustic biofeedback
Behavioral
Lead sponsor
New York University
Other
Eligibility
9 Years to 17 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Bloomfield, New Jersey • New York, New York • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 25, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Therapy for Children With Neuroblastoma

NCT00135135
View directory record Official record
Conditions
Neuroblastoma
Interventions
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid, Radiation therapy, Surgery, Peripheral Stem cell transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Oct 25, 2026, 10:13 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

NCT02519348
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Bevacizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 10:13 PM EDT